Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. filed this Form 8-K on January 29, 2015, to report the completion of a merger with Aquarius Biotechnologies, Inc. Aquarius is a clinical-stage biopharmaceutical company focused on infectious diseases using a proprietary cochleate drug delivery platform. The merger became effective on January 29, 2015, making Aquarius a wholly-owned subsidiary of Matinas.
Key Financial Metrics and Transaction Terms
This filing details a stock-for-stock transaction rather than providing standard financial performance metrics such as revenue or cash flow for the period.
- Closing Consideration: Matinas issued 4,608,020 shares of its common stock at closing.
- Maximum Closing Shares: The number of shares issued at closing is capped at 5,000,000.
- Milestone Consideration: Matinas may issue up to an additional 3,000,000 shares upon achieving specific milestones:
- 1,500,000 shares upon dosing the first patient in a Phase III trial for a product using Aquarius technology.
- 1,500,000 shares upon FDA approval of the first New Drug Application (NDA) for a product using Aquarius technology.
- Ownership Structure: Following the issuance of closing shares, former Aquarius stockholders own approximately 8% of Matinas' fully diluted shares, while existing Matinas stockholders own approximately 92%.
- Financial Statements: The filing states that financial statements of the acquired business and pro forma financial information will be filed by amendment within 71 calendar days.
Material Changes
The primary material change is the acquisition of Aquarius Biotechnologies, Inc. and its cochleate technology platform. This transaction expands Matinas' portfolio to include a broad-spectrum anti-fungal drug candidate (amphotericin B) which has completed a single-dose Phase 1 study. The transaction was structured as a tax-free reorganization for U.S. federal income tax purposes.
Outlook, Risks, and Contingencies
Technology Transfer Contingency: The Merger Agreement includes a provision requiring Matinas to transfer Aquarius' cochleate technology back to former Aquarius shareholders if:
- No milestone events occur within two years of the merger effective date.
- Matinas discontinues efforts to develop or commercialize the technology (evidenced by omitting the technology from at least two consecutive reports to Rutgers).
- No unresolved indemnification claims are pending as of the transfer date.
Risks: The filing notes that representations and warranties in the Merger Agreement were made for allocating contractual risk and may not reflect the actual state of facts. Investors are cautioned not to rely on these representations as characterizations of actual circumstances.
Key Facts for Investor Verification
- Verify the exact number of shares issued at closing (4,608,020) and the potential dilution from the 3,000,000 milestone shares.
- Confirm the timeline for the upcoming amendment filing containing the financial statements of Aquarius and pro forma information (due within 71 days of the initial report).
- Monitor the development status of the amphotericin B candidate to assess the likelihood of triggering the milestone share issuances.
- Review the specific terms of the technology transfer clause to understand the conditions under which Matinas could lose the acquired assets.